Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Sales | 121,703 | 65,316 | 55,221 | 25,354 | 53,665 |
| Cost of Goods | 26,272 | 5,568 | 5,740 | 5,787 | 16,687 |
| Gross Profit | 95,431 | 59,748 | 49,481 | 19,567 | 36,978 |
| Operating Expenses | 18,079 | 20,017 | 20,666 | 23,577 | 69,727 |
| Operating Income | 77,624 | 40,299 | 29,555 | -3,223 | -32,062 |
| Interest Expense | 5,036 | 4,990 | 5,004 | 5,348 | 3,731 |
| Other Income | 661 | 961 | 1,324 | 2,479 | 1,333 |
| Pre-tax Income | 73,249 | 36,270 | 25,875 | -6,092 | -34,460 |
| Income Tax | 85 | 63 | 58 | 11 | -63 |
| Net Income Continuous | 73,164 | 36,207 | 25,817 | -6,103 | -34,397 |
| Net Income | $73,164 | $36,207 | $25,817 | $-6,103 | $-34,397 |
| EPS Basic Total Ops | 0.53 | 0.27 | 0.19 | -0.04 | -0.24 |
| EPS Basic Continuous Ops | 0.54 | 0.27 | 0.19 | -0.04 | -0.24 |
| EPS Diluted Total Ops | 0.51 | 0.25 | 0.19 | -0.04 | -0.24 |
| EPS Diluted Continuous Ops | 0.52 | 0.25 | 0.19 | -0.04 | -0.24 |
| EBITDA(a) | $82,382 | $44,934 | $34,077 | $1,121 | $-29,563 |